I just wanted to express why I believe HER-Vaxx is on target to...

I just wanted to express why I believe HER-Vaxx is on target to show a significant OS rate (potentially better than the interim data)

Last April IMU released an ASX announcement that the HER-Vaxx Phase2 interim data was being presented the to the American Association of Cancer Research (ACCR) with the following excerpt:

I have highlighted the median interim OS (14.2 months) compared to the Chemo only (8.8 months) this is important as the last patient was dosed on 7th Jan 2021, we are now heading towards 15 months since this announcement and still waiting for disease progression to gain the final OS data. (LC mention in a recent interview that we are still waiting).

The same AACR announcement mentioned that they expected the PFS & OS readout to be in 2021 (highlighted below), we are now just about to head into Q2 2022 and still waiting for the final "event/s" to occur for OS data, my view is that the data will be better than they expected back when the ACCR presentation was held because of the additional time that has now elapsed.

I also believe that the recent activity around HER-vaxx collaborations with BP indicates the same belief (or knowledge).


My views only not financial advice
Capt